Absolutely. On one hand I'm ever so slightly concerned about the meteoric share price. But on the other hand I believe it to be substantiated given the increasing evidence that (a) the technology works, (b) there is a significant demand for the technology, (c) management have ticked every goal thus far and on time, and (d) they're doing it with total credibility and scientific rigour. It's certainly over-priced as a pre-revenue company, for sure. But the credibility behind their team and their strategy cannot be disregarded.
Commercialisation is imminent, and the MFF grant might solidify EMV's potentially significant impact to detect and subsequently prevent death associated with stroke (excluding altogether the scanner for fatty liver disease and any other translational applications).
Any pullback and I'll continue to load up.
GLTAH.
Chart, page-1108
-
- There are more pages in this discussion • 1,741 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.12 |
Change
-0.030(1.40%) |
Mkt cap ! $181.1M | |||
| Open | High | Low | Value | Volume |
| $2.15 | $2.18 | $2.10 | $93.15K | 43.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 194 | $2.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.15 | 11452 | 1 |
View Market Depth
| Last trade - 15.51pm 16/08/2024 (20 minute delay) ? |
| EMV (ASX) Chart |